
US prospects, new drugs make Glenmark look better
ET Intelligence Group: The stock of Glenmark Pharmaceuticals has shown marginal improvement of 2% in a month, amid higher market volatility, compared with a 7% loss incurred in the prior three months. The positive sentiment follows expectations of a strong …